Stoke Therapeutics Inc

Company Profile

• Business description

  Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.

• Contact

  45 Wiggins Avenue
  BedfordMA01730
  USA

  T: +1 781 430-8200

  https://www.stoketherapeutics.com

• Sector

  Healthcare

  Stock type

  Defensive

• Industry

  Biotechnology

  Fiscal Year End

  31 December 2025

  Employees

  128